Last reviewed · How we verify
Citrate-Free Mirikizumab
Citrate-Free Mirikizumab is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development. Also known as: LY3074828.
At a glance
| Generic name | Citrate-Free Mirikizumab |
|---|---|
| Also known as | LY3074828 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants (PHASE1)
- A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Citrate-Free Mirikizumab CI brief — competitive landscape report
- Citrate-Free Mirikizumab updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Citrate-Free Mirikizumab
What is Citrate-Free Mirikizumab?
Citrate-Free Mirikizumab is a Small molecule drug developed by Eli Lilly and Company.
Who makes Citrate-Free Mirikizumab?
Citrate-Free Mirikizumab is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).
Is Citrate-Free Mirikizumab also known as anything else?
Citrate-Free Mirikizumab is also known as LY3074828.
What development phase is Citrate-Free Mirikizumab in?
Citrate-Free Mirikizumab is in Phase 1.
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Also known as: LY3074828
- Compare: Citrate-Free Mirikizumab vs similar drugs
- Pricing: Citrate-Free Mirikizumab cost, discount & access